Start with the question, not the folder
A second opinion is only as sharp as the question behind it. "Is my treatment right?" is hard to answer. "My pathology shows muscle-invasive disease and I have been offered radical cystectomy — should I consider neoadjuvant chemotherapy first, and does the staging support that?" gives a clinician something to work with. Before you assemble anything, write two or three sentences describing your diagnosis as you understand it, the treatment already given or planned, and the specific decision you are facing.
That framing changes which records matter. If the question is whether the original pathology was read correctly, the slides and blocks move to the top of the list. If the question is whether staging is complete, the imaging files and the radiology reports matter most. If the question is about a choice between bladder removal and bladder-preserving treatment, the team will want the cystoscopy findings, the depth of invasion, and any history of previous bladder tumours or intravesical therapy.
Keep the summary short at first contact. A brief message with your diagnosis, stage as reported, treatments to date and your main question is enough for an initial review. Do not send passport numbers, payment details or a complete medical archive through a first enquiry form. The detailed exchange comes after someone confirms what is needed and how to send it securely.
Pathology: the report, the slides and the blocks
For bladder cancer, the pathology report is often the single most consequential document. A reviewing pathologist needs more than a typed summary. Ask your treating hospital what it can release: the full report, the stained slides, and the paraffin blocks from which new sections can be cut. The blocks matter because a reviewer may want to run additional stains, for example to check for variants or to assess markers that affect treatment choices.
The report should state the tumour type and grade, how deep it invades, whether the muscularis propria is involved, whether there is lymphovascular invasion, and the status of any nodes or margins from a prior resection. If a transurethral resection was done, the report should indicate whether the specimen included muscle, because that determines how confidently a non-muscle-invasive diagnosis can be made. If any of these elements are missing or unclear, that is itself a question for the reviewing team.
Practical release can be slow. Hospitals differ in whether they lend slides and blocks, provide recuts, or issue digital scans. Ask your current hospital what its process is and how long it takes, rather than assuming a standard. If slides cannot travel, a digital pathology image may be acceptable to some reviewers, but whether it is sufficient for a particular question is a clinical judgement, not a shipping decision.
A pathology review is not a formality. It can confirm the original reading, add detail, or occasionally change the interpretation in ways that alter treatment. It also has limits: a review of the same material cannot always resolve every uncertainty, and the reviewing pathologist may recommend additional testing. Treat the review as one input into the treating team's decision, not a verdict on its own.
Imaging: reports are not the same as images
Radiology reports summarise what a radiologist saw, but a second-opinion team often wants to look at the images themselves. For bladder cancer this typically means CT or MRI of the abdomen and pelvis, and sometimes imaging of the chest. Ask for the original DICOM files on a disc or through a secure link, not only the printed report.
The reports still matter, because they record measurements, dates and the radiologist's interpretation at the time. Send both where possible. If you have had imaging at more than one hospital, include the earlier studies too, since comparison over time can clarify whether a finding is new or stable.
Staging is a clinical assessment that draws on imaging, examination and pathology together. A reviewing team may conclude that the available imaging is adequate, or it may say that further assessment is needed before a treatment recommendation can be firm. That is a legitimate outcome of a second opinion, not a failure of the process. Ask directly what remains uncertain and what would resolve it.
Treatment history and operative records
Bladder cancer care is often a sequence rather than a single event. The reviewing team needs to see that sequence: cystoscopy reports, operation notes from any transurethral resection, pathology from each procedure, and a record of intravesical treatments such as BCG or chemotherapy instilled into the bladder, with dates and number of courses. If you have received systemic chemotherapy or immunotherapy, include the drug names, dates and the response recorded by your treating team.
A short chronological summary that you write yourself is genuinely useful here. List each procedure and treatment with its date and the hospital where it happened. It does not need to be elegant. It helps the reviewer see the pattern quickly and flags gaps that need filling.
Include relevant background too: kidney function results, because some treatments depend on it; any history of upper urinary tract tumours; and other significant conditions and current medicines. Do not stop or change any medicine on your own while seeking an opinion. Prescribing and medicine changes belong to licensed clinicians who know your full history.
What a records-based opinion can and cannot settle
A review of records can clarify the pathology, comment on whether the staging appears complete, outline treatment options that international guidelines describe, and identify questions worth raising with your local team. It can also point out where the record is insufficient and what further information would help.
It cannot examine you. A clinician reading a file cannot palpate an abdomen, assess your fitness for a particular operation, or confirm how you have tolerated prior treatment. Those judgements require direct assessment. A records-based opinion is therefore a step toward a decision, not a substitute for the treating hospital's own evaluation and acceptance process.
It is also not a promise of access to any particular treatment in China. Availability of specific therapies, devices or clinical trials depends on the hospital, the clinician's assessment and current regulations. If a trial or a specialised therapy is part of your question, say so explicitly, and expect the answer to distinguish between a review of eligibility criteria and confirmed enrolment.
Ask the reviewing team to state its confidence and its limits. A useful opinion tells you what it concluded, what evidence it relied on, and what it could not determine from the records alone.
Sending records and agreeing the next step
Once you have a short summary and the core documents, the practical question is where to send them and in what form. Ask the receiving service how it prefers to receive large files, whether translated summaries are needed, and whether original slides must be couriered or can be digitised. These arrangements vary, so confirm them rather than assuming.
If you are considering care in China, the relevant specialty context is urology, and the surgical reference for muscle-invasive disease is radical cystectomy. Reading those pages before you send records can help you frame your question, but they do not replace an individual assessment.
An initial enquiry is free and does not require buying a proxy consultation. A brief summary of your diagnosis and question is enough to start; the team can then tell you what records to send and whether a records-based review or a specialist appointment fits your situation. The hospital and its clinicians decide suitability, treatment and acceptance.
A sensible next step is to write your two or three sentence question, list your procedures and treatments with dates, and ask your current hospital what it can release in the way of pathology slides, blocks and imaging files. Send the summary first and let the receiving team guide the rest.
Sources & scope of this guide
References and official service information relevant to this guide.
- radical cystectomy
- Related treatment reference
- European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer
- European Association of Urology guidelines on non-muscle-invasive bladder cancer
- National Cancer Institute: Bladder Cancer Treatment
- American Urological Association: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer guideline
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
